<DOC>
	<DOCNO>NCT00980785</DOCNO>
	<brief_summary>Angiotensin convert enzyme inhibitor ( ACE-I ) group blood pressure-lowering medicine . Some study suggest ACE-I , ramipril , may help prevent Alzheimer 's disease ( AD ) . The purpose research see ramipril affect substance body call beta-amyloid . Beta-amyloid find brain liquid around brain spinal cord . High amount beta-amyloid may associate great risk get Alzheimer 's disease . This study see ramipril low amount beta-amyloid spinal fluid . This study also see ramipril affect blood vessel function memory thinking . The investigator hope future study show whether ramipril might prevent memory loss decrease chance develop Alzheimer 's disease .</brief_summary>
	<brief_title>Studying Effects Antihypertensives Individuals Risk Alzheimer 's</brief_title>
	<detailed_description>High blood pressure ( BP ) midlife predictive Alzheimer 's disease ( AD ) later life . Similarly , reduction BP associate protection AD . Treatment antihypertensive medication , specifically angiotensin convert enzyme inhibitor ( ACE-I ) ramipril , associate 55 % reduction prevalence AD , suggest potentially promising role ACE-I prevention AD . It unknown however 1 ) whether ACE-Is effect CSF Aβ level human animal model 2 ) whether ACE-Is induce change associate vascular function ( i.e . level CSF angiotensin convert enzyme ( ACE ) peripheral endothelial function ) 3 ) whether interaction ACE-I-induced change CSF Aβ , CSF ACE indices vascular function . One mechanism antihypertensive may protect AD via Aβ neuropathology . In order well understand mechanism ACE-I may modify CSF Aβ possibly AD risk , propose randomize , double-blind , placebo-controlled pilot clinical trial , enrol 20 middle-aged ( age range 40 - 65 year ) , mildly hypertensive ( 130 - 160 mmHg mean systolic 85 - 100 mmHg mean diastolic ) participant , adult child individual AD . The main objective trial examine effect ACE-I , ramipril , 1 ) CSF Aβ level 2 ) CSF ACE level 3 ) peripheral endothelial function measure brachial artery flow-mediated vasodilation ( FMD ) aortic augmentation index ( AAIx ) , middle-aged adult mildly elevate BP , increase risk develop AD .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Between age 40 65 Mean rest blood pressure 130160 systolic 85100 diastolic Parent Alzheimer 's Disease Current involvement another investigational drug trial . Potassium &gt; 5.0 Dementia base DSMIV criterion MMSE &lt; 27 Current blood pressure medication ( &lt; 4 month screen ) Weight loss medication Contraindications LP Know diagnosis history hospitalization due congestive heart failure Elevated creatinine ( female &gt; 1.3 mg/dL male &gt; 1.4 mg/dL baseline ) Diabetes Type I II Know adverse reaction ACEI angiotensin receptor blocker Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Hypertension</keyword>
</DOC>